1. Introduction {#sec1-marinedrugs-18-00058}
===============

Microbial secondary metabolites with widely divergent chemical structures have been regarded not only as prolific drug candidates, but also an inspiration for the starting point of drug design \[[@B1-marinedrugs-18-00058]\]. For half a century, antibiotics derived from microorganisms have become the leading drugs in different clinical fields due to their distinct structures and excellent activities \[[@B2-marinedrugs-18-00058],[@B3-marinedrugs-18-00058]\]. However, the emerging of drug-resistant bacteria and drug-resistant tumors has prompted people to search for new drugs and novel mechanisms of action \[[@B4-marinedrugs-18-00058],[@B5-marinedrugs-18-00058]\]. More recently, the marine environment is considered as an abundant microbial resource due to its complex ecological environment and relatively harsh living conditions \[[@B6-marinedrugs-18-00058],[@B7-marinedrugs-18-00058]\], which implies there are enormous unexplored secondary metabolites and their biosynthetic gene clusters to be discovered and characterized. Thus, marine microorganisms appear to be a treasure trove of new active microbial drugs \[[@B8-marinedrugs-18-00058],[@B9-marinedrugs-18-00058]\]. Recent studies have fully demonstrated that marine actinomycetes can produce a variety of secondary metabolites with diverse biological activities, including antibacterial \[[@B10-marinedrugs-18-00058],[@B11-marinedrugs-18-00058]\], anti-tumor \[[@B12-marinedrugs-18-00058]\], anti-inflammatory \[[@B13-marinedrugs-18-00058]\], immune regulation \[[@B14-marinedrugs-18-00058]\], anti-parasitic \[[@B15-marinedrugs-18-00058]\], anti-oxidation \[[@B16-marinedrugs-18-00058]\], and anti-virus \[[@B17-marinedrugs-18-00058]\].

The naturally occurring aromatic γ-pyrone structure, a major class of polyketides, is widely found in bioactive natural products, and its structural diversity and various biological activities make it important in the pharmaceutical industry \[[@B18-marinedrugs-18-00058],[@B19-marinedrugs-18-00058]\]. For example, the flavonoids widely distribute in plant are benzopyrone derivatives \[[@B20-marinedrugs-18-00058]\]. The (bis-) naphtho-γ-pyrones compounds are mostly discovered in secondary metabolites of fungi \[[@B21-marinedrugs-18-00058]\]. Some compounds with more complex structures, which contain anthraquinone-γ-pyrone structural units, such as parimycin \[[@B22-marinedrugs-18-00058]\], saliniquinones \[[@B23-marinedrugs-18-00058]\], and hedamycin \[[@B24-marinedrugs-18-00058]\] are present in secondary metabolites of bacteria. Given the significant drug development potential of this class of compounds, it is of great interest to discover new compounds containing anthraquinone-γ-pyrone core in bacterial secondary metabolites \[[@B25-marinedrugs-18-00058]\].

Binzhou shell island is one of the three old shell ridges in the world which formed over thousands of years in the Yellow River Delta, representing a great repertoire for the study of the marine species biodiversity \[[@B26-marinedrugs-18-00058],[@B27-marinedrugs-18-00058]\]. Its unique geographical environment results in a unique ecosystem, which raises unique microorganisms producing novel secondary metabolites \[[@B28-marinedrugs-18-00058]\]. In this study, the chemical composition of the marine *Streptomyces* sp. shell-016 from the Binzhou shell dike island was studied. Four new polyketides, named shellmycin A--D (**1**--**4**), containing the tetrahydroanthra-γ-pyrone skeleton, were isolated ([Figure 1](#marinedrugs-18-00058-f001){ref-type="fig"}). The structures and relative configurations of the compounds were elucidated by NMR and high-resolution mass spectrometry (HR-MS). The absolute configuration of **1** was clarified by X-ray single crystal diffraction. This study also investigated the antibacterial activity and anticancer activity of **1**--**4**, indicating that this group of compounds has moderate antibacterial activity and strong anticancer activity.

2. Results and Discussion {#sec2-marinedrugs-18-00058}
=========================

2.1. Extraction and Purification {#sec2dot1-marinedrugs-18-00058}
--------------------------------

The strain *Streptomyces* sp. shell-016 was cultured for 11 days on ISP3 agar plates at 28 °C. The 10 L fermented agar were diced and extracted overnight three times with ethyl acetate: methanol: acetic acid (80:15:5, v/v) at room temperature. After removing the organic solvents under vacuum, the crude extract was partitioned between double-distilled water and ethyl acetate (1:1, v/v). Then the ethyl acetate extract was dried with sodium sulfate (anhydrous) and partitioned between methanol and petroleum ether (1:1, v/v). The methanol layer was concentrated under vacuum to obtain the defatted methanol extract (3.9 g), which was subjected to MPLC over reversed phase C-18 silica gel, Sephadex LH-20 and HPLC to yield compounds **1**--**4** ([Figure 1](#marinedrugs-18-00058-f001){ref-type="fig"}).

2.2. Structure Elucidation {#sec2dot2-marinedrugs-18-00058}
--------------------------

Compound **1** was isolated as a yellow oil, and a yellow crystal was obtained by recrystallization with methanol/acetone (5:1) mixed solvent. The high resolution ESI-MS gave a quasi-molecular ion at *m*/*z* 469.1493 \[M + H\]^+^ ([Figure S1](#app1-marinedrugs-18-00058){ref-type="app"}), which is consistent with the molecular formula C~25~H~24~O~9~ (calcd. for C~25~H~25~O~9~^+^, 469.1493). The NMR spectra of **1** ([Figures S2--S7](#app1-marinedrugs-18-00058){ref-type="app"} and [Table 1](#marinedrugs-18-00058-t001){ref-type="table"}) displayed 12 signals, including two methyls, three methylenes, three olefinic protons, and two aromatic protons. The ^13^C-NMR spectroscopic data of **1** showed three carbonyl signals at δ~C~ 175.7, 182.1, and 185.4, and eight quaternary carbon signals (δ~C~ 165.8, 159.1, 147.8, 142.6, 138.0, 120.6, 114.7, and 113.3), which are characteristics for the existence of the ring-fused aromatic system. The presence of ^1^H-^1^H spin--spin coupling system in the COSY experiment of **1** from H-8 to H-9 and H-9 to H-10 combined with the HMBC correlations from H-10 to C-11 and C-11a, and another HMBC correlations from H-8 to C-7a and C-7 confirmed the structure of ring A. The chemical shift of H-8 was as high as 4.95 ppm indicated that it was connected with a hydroxyl group. Two aromatic proton signals suggested that this compound has a multi-substituted naphthalene structure. Additionally, the HMBC correlations from H-7 to C-8, C-6 and C-11a combined with the HMBC correlations from H-6 to C-7, C-13, C12a, C-4a revealed the substitution of naphthalene rings. More in-depth, the chemical shift of C-12 moved to the downfield at 165.8 ppm, suggesting that the C-12 was connected with an oxygen atom. Then, the structure of ring B, C, and D was confirmed. The distinct signals of H-13 (δ~H~ 4.16, 4.26) and the HMBC correlations from this nucleus to C-13-COOH, C-6, and C-4a gave the information that the carboxymethyl group was connected with C-5 on the naphthalene core. The γ-pyrone structure (ring A) formed by C-2, C-3, C-4, C-4a, and C-12b was also deduced by the HMBC correlations from H-3 to C-2, C-4, C-4a. According to the ^1^H-^1^H COSY of compound **1**, there was still a very significant spin-spin coupling system from H-19 to H-18 then to H17 and stopped at H-16. The chemical shift of H-17 (5.73 ppm) and H-18 (5.88 ppm) suggested an ethylenic bond between C-17 and C-18. It was clear to verify the geometry of the C-17/18 double bond is *Z* according to the *cis*-^1^H--^1^H coupling between H-17 and H-18 (*J* = 11.7 Hz) and the single crystal X-ray diffraction. The side chain structure was elucidated by HMBC correlations from H-17 to C-16, H-16 to C-2, C-3, and C-15 combined with the HMBC correlations from H-15 to C-2, C-3, C-16, and from H-3 to C-14. Then the planar structure of compound **1** was illustrated. As shown in [Figure 2](#marinedrugs-18-00058-f002){ref-type="fig"}, the NOESY cross-peaks from H-3 to H-15, H-15 to H-16, and H-15 to H-17 ([Figure 2](#marinedrugs-18-00058-f002){ref-type="fig"}, mixing time 700 ms) were observed but that cannot give definite evidence to support the 14*S*\*, 16*R*\* relative configuration. Compound **1** can form fine crystals in methanol and acetone mixtures, so the single crystal X-ray diffraction was tested, and the absolute configuration of compound **1** was determined ([Figure 3](#marinedrugs-18-00058-f003){ref-type="fig"}, Crystal structure reports see [Supplementary Materials](#app1-marinedrugs-18-00058){ref-type="app"}; CCDC deposition number: 1970563). Based on the above analyses, the gross structure of **1** was deduced as a new polyketide, for which we proposed the name shellmycin A.

Compound **2** was isolated as a yellow oil. The molecular formula of **2** was assigned as C~25~H~26~O~9~ by interpretation of a protonated molecular ion peak at *m*/*z* 471.1648 \[M + H\]^+^ (calcd. for C~25~H~27~O~9~^+^, 471.1650) in the HR-MS spectrum ([Figure S8](#app1-marinedrugs-18-00058){ref-type="app"}). Compared to **1**, compound **2** has two more hydrogen atoms. The NMR data ([Figures S9--S14](#app1-marinedrugs-18-00058){ref-type="app"}) demonstrated that compound 2 has a multi-substituted naphthalene structure ([Table 2](#marinedrugs-18-00058-t002){ref-type="table"}), just like **1**. The same noticeable ^1^H-^1^H COSY cross-peaks from H-10 to H-9 and H-9 to H-8 additional with the HMBC correlation from H-10 to C-11a and H-8 to C-7 suggested the structure of the ring A is the same as compound **1**. Similarly, the HMBC correlation from H-7 to C-8, C-6, and another HMBC correlation from H-6 to C-7, C-13, and C-4a as well as the HMBC correlation from H-13 to C-6 and C-4a suggested that the compound **2** has the same naphthalene core with **1** ([Figure 4](#marinedrugs-18-00058-f004){ref-type="fig"}). Similarly, the HMBC correlation from H-3 to C-4a, C-14, and C-2 could also ascertain the γ-pyrone structure, and its substitution type was the same as **1**. The apparent difference of the ^1^H-NMR and ^13^C-NMR between **2** and **1** was that the characteristic peaks of the double bond disappeared. Distinct ^1^H-^1^H COSY cross peaks from H-16 to H-17 then from H-17 to H-18 then to H-19, and their HMBC correlations gave the evidence, which confirmed the side chain structure of compound **2**. Same as **1**, the NOESY cross-peaks from H-3 to H-15, H-15 to H-16, and H-15 to H-17 cannot give definite evidence to support the 14*S*\*, 16*R*\* relative configuration. The 8S\* relative configuration was confirmed from the single-crystal structure of 1 and proposed biosynthetic pathways. Based on comparison of the ECD spectra between **1** and **2**, the absolute configuration of **2** was assigned ([Figure 5](#marinedrugs-18-00058-f005){ref-type="fig"}). Thus, the structure of shellmycin B (**2**) was proposed.

The molecular formula of **3** and **4** were both assigned as C~25~H~26~O~9~ by interpretation of a protonated molecular ion peak at *m*/*z* 469.1491 and 469.1494 (calcd for C~25~H~25~O~9~^+^, 469.1493) in the HR-MS spectrum ([Figures S15 and S22](#app1-marinedrugs-18-00058){ref-type="app"}). Interestingly, these two compounds had almost identical NMR spectra. These facts showed that compound **1** and **4** have the same planar structure. The comparison of its ^1^H and ^13^C NMR data ([Table 3](#marinedrugs-18-00058-t003){ref-type="table"} and [Table 4](#marinedrugs-18-00058-t004){ref-type="table"}, [Figures S16--S21](#app1-marinedrugs-18-00058){ref-type="app"}; [Figures S23--S28](#app1-marinedrugs-18-00058){ref-type="app"}) with those of **1** indicated that both structures contain the same backbone fused with the γ-pyrone and naphthalene ring. The ^1^H-^1^H COSY from H-19 to H-18 (δ~H~ 4.32) gave the evidence that C-18 is connected with a hydroxy-substituted carbon (C18, δ~C~ 69.4). Then the four-carbon chain from C-16 to C-19 was established according to ^1^H--^1^H COSY correlations, along with the HMBC correlations from the protons of H-16, H-17, H-18, and H-19 to the corresponding carbons ([Figure 6](#marinedrugs-18-00058-f006){ref-type="fig"}). The geometry of the C-16/17 double bond was determined to be *E*-form based on the *trans*-^1^H--^1^H coupling constants between H-16 and H-17 (*J* = 15.5 Hz). The 8*S*\* relative configuration was proposed based on analogy to the single-crystal structure of **1** and proposed biosynthetic pathways. Most impressive of all, the **3** and **4** have the same planar structure but difference retention time between **3** and **4** is likely due to the stereochemistry of C-14 and C-18. In compound **4**, a distinct NOESY cross peak was found between H-15 and H-16, but there was not any signal between H-15 and H-17. A very different NOESY correlation from H-15 to both H-16 and H-17 suggested that there have some difference between **3** and **4**. Based on the ECD spectra and calculated spectra of **3** and **4**, the absolute configurations of **3** and **4** were assigned ([Figure 7](#marinedrugs-18-00058-f007){ref-type="fig"}) that the stereochemistry of C-14 should be *R\** in **4** but *S\** in **3**. Thus, **3** and **4** are a pair of stereoisomers, called shellmycin C (**3**) and shellmycin D (**4**).

2.3. Bioactivity Assay {#sec2dot3-marinedrugs-18-00058}
----------------------

The MICs were determined to evaluate the antimicrobial activities of the shellmycins. *Candida albicans* ATCC18804 was used as a fungal indicator pathogen, *Staphylococcus aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212, *Bacillus subtilis* ATCC 6633, *Pseudomonas aeruginosa* ATCC 27853, and *Mycobacterium smegmatis* ATCC 700084 were used as the bacterial indicator pathogen. As a result, compounds **1**--**4** exhibited moderate anti-microbial activity to the *Bacillus subtilis, Staphylococcus aureus*, and *Enterococcus faecalis* but did not show any activity to *Candida albicans*, *Pseudomonas aeruginosa*, and *Mycobacterium smegmatis* ([Table 5](#marinedrugs-18-00058-t005){ref-type="table"}).

Shellmycins exhibited cytotoxicity at the micro molarity level against five tumorous human cell lines ([Table 6](#marinedrugs-18-00058-t006){ref-type="table"}). The resazurin-based cell viability assays showed that the four compounds all inhibited cell growth for both 24 h and 72 h treatment. In general, compound **1**, **2**, and **4** showed higher cytotoxicity than compound **3**, with the IC~50~ ranging from 0.69 µM to 3.11 µM at 72 h. In addition, certain types of tumor cells like A375, HepG2, and HT29 are more sensitive to shellmycins. Since compound **3** and **4** are enantiomers, the different anticancer activity of **3** and **4** lead to a conclusion that the stereochemistry of the C-14 is an important factor for the bioactivity of shellmycins. The strong anticancer activity of **1**, **2**, and **4** indicates the potential of such compounds as a template or scaffold to develop structurally related anticancer drugs.

2.4. Proposed Biosynthesis Pathway {#sec2dot4-marinedrugs-18-00058}
----------------------------------

Upon comparing the antibiotic and anticancer activities of different shellmycins, the SAR results then will be used to guide biosynthetic engineering efforts. The remarkable activity of compound **1**, **2**, and **4** implies the importance of the stereochemistry of the side chains. The biosynthesis, incorporation, and post-modification of the side chain, therefore, are significant in the following study. In our proposed biosynthetic pathway of shellmycins, the aromatic polycyclic skeleton of shellmycin suggests that a type-II PKS should be involved in the biosynthesis \[[@B29-marinedrugs-18-00058],[@B30-marinedrugs-18-00058]\]. The methylated 6-carbon side chain of shellmycin is proposed to be synthesized via a bacterial type I PKS, incorporating acetyl-CoA, malonyl-CoA, and methyl-malonyl-CoA sequentially. Here we predict that the nascent product of this type I PKS is methyldiene-S-ACP, which may help to allow a series of epoxidations and rearrangements to take place ([Figure 8](#marinedrugs-18-00058-f008){ref-type="fig"}). This hexenoate starter unit will then be loaded to the type II PKS to form the final tetrahydroanthra-γ-pyrone core after nine rounds of chain elongation ([Figure 8](#marinedrugs-18-00058-f008){ref-type="fig"}). According to the research done by Thorson and co-workers on the biosynthesis of hedamycin, which shares the similar core structure with shellmycin, they suggested that the unusual hexenoate starter unit is recognized by a ketosynthase (KSIII), and loaded onto the PKS by a putative acyl carrier protein (ACP) \[[@B31-marinedrugs-18-00058]\]. In our case, a gatekeeper KSIII and ACP might also be good indications for unusual starter unit incorporation ([Figure 8](#marinedrugs-18-00058-f008){ref-type="fig"}). Oxidative tailoring reactions will then take place on both tetrahydroanthra-γ-pyrone core and side chains. Epoxidation followed by hydrolysis of the diene side chain would form compound **1**, with further reduction in the case of compound **2**. An enzymatic catalyzed rearrangement hydrolysis of the mono-epoxide will result in compounds **3** and **4**. In summary, there are many very intriguing aspects in the proposed biosynthetic mechanism. Mechanistic details will be revealed in the further studies.

3. Materials and Methods {#sec3-marinedrugs-18-00058}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-18-00058}
------------------------------------

NMR spectra were recorded on a Bruker Avance DRX 500 MHz NMR spectrometer (Bruker Daltonics Inc., Billerica, Massachusetts) with tetramethylsilane (TMS) as an internal standard. HR-ESIMS were measured on an LTQ-Orbitrap XL. UV spectra were recorded on a Persee TU-1810 spectrometer (Beijing Persee General Instrument Co. Ltd., Beijing, China). Optical rotations were measured on SGW-2 digital polarimeter (Shanghai Precision Instrument Co., Ltd., Shanghai, China) at 25 °C. HPLC separations were mainly performed on two HPLC systems: Agilent 1260 instrument equipped with Phenomenex Kinetex PS C18 column (3.5 µm, 10 × 150 mm). Waters PrepLC 150 HPLC System equipped with Waters 996 Photodiode Array Detector using Phenomenex Kinetex PS C18 column (5 µm, 20 × 150 mm). Sephadex LH-20 was obtained from the GE Amersham Biosciences (Piscataway, New Jersey, USA). Reversed-phase C-18 silica gel for column chromatography was purchased from Merck (Darmstadt, Germany). Silica gel GF~254~ for thin-layer chromatography (TLC) was obtained from Qingdao Marine Chemical Ltd. (Qingdao, China).

3.2. Biological Materials {#sec3dot2-marinedrugs-18-00058}
-------------------------

The *Streptomyces* sp. shell-016 was isolated from the shell sediment of the Binzhou Shell Dike Island and Wetland National Nature Reserve, China (38°13′17″ N, 117°57′29″ E). The identification of the actinomycete strain was based on 16S rRNA gene sequence analysis. The DNA preparations were used as a template for partial 16S rRNA gene PCR amplification applying the universal primers (27f: 5′-AGAGTTTGATCMTGGCTCAG-3′, 1492r: 5′-TACGGTTACCTTGTTACGACTT-3). The reaction mixture (50 µL) includes 10--100 ng genomic DNA, 20 pmol of each universal primer, 25 µL GoTaq Master Mixes (Promega Corporation, Madison, WI, USA). The PCR cycling program was as follows: initial denaturing for 2 min at 95 °C, 30 cycles of denaturation for 30 s at 95 °C, annealing for 30 s at 58 °C, extension for 60 s at 72 °C, and final extension for 5 min at 72 °C. The sequences of 16S rRNA were assigned into taxonomic ranks (genus) using Ribosomal Database Project (RDP) Classifier. The 16S rRNA gene sequence of the strain displayed 98% similarity with type strains of *Streptomyces achromogenes* subsp. rubradiris strain NBRC 14,000 (NR_112428.1) and *Streptomyces vellosus* strain HR 29 (KT438921.1).

3.3. Fermentation and Extraction {#sec3dot3-marinedrugs-18-00058}
--------------------------------

The spores of *Streptomyces* sp. shell-016 were cultured with ISP2 agar medium (yeast extract 4.0 g, malt extract 10.0 g, glucose 4.0 g, agar 15 g, dd H~2~O 1000 mL, pH 7.2) in Petri dishes as the seed culture. The fermentation (10 L) was performed on ISP3 agar medium (oatmeal 20 g, saline salt 1 mL (saline salt contained FeSO~4~·7H~2~O 0.1 g, ZnSO~4~·7H~2~O 0.1 g, MnCl~2~·4H~2~O 0.1 g, dd H~2~O 100 mL), dd H~2~O 1000 mL, agar 15 g, pH 7.2) for 12 d at 28 °C in Petri dishes. To extract the metabolites, the culture agar was diced and extracted overnight three times with ethyl acetate: methanol: acetic acid (80:15:5, v/v) at room temperature. After removing the organic solvents under vacuum, the crude extract was partitioned between purified water and ethyl acetate (1:1, v/v). Then the ethyl acetate extract was dried with sodium sulfate (anhydrous) and partitioned between methanol and petroleum ether (1:1, v/v). The methanol layer was concentrated under vacuum to obtain the defatted methanol extract (3.9 g).

3.4. Purification of the Compounds {#sec3dot4-marinedrugs-18-00058}
----------------------------------

The methanol extract (3.9 g) was fractionated by MPLC (200 g RP-18 silica gel; 30%, 50%, 70%, and 100% methanol, 1 L each, respectively). According to the HPLC detection results, Fr. 3--5, Fr. 9--12, and Fr. 13--15 were combined and marked as Fr. A and Fr. B. Fr. A was subject to Sephadex LH-20 (60 g; methanol) to obtain Fr. A1. Fr. A1 was purified by reversed phase HPLC (Agilent 1260 instrument equipped with Phenomenex Kinetex PS C18 column, 3.5 µm, 10 × 150 mm) eluted with 20% acetonitrile at a flow rate 3.2 mL/min to obtain **3** (*t~R~* = 15.9 min, 2.2 mg) and **4** (*t~R~* = 18.6 min, 1.5 mg).

Fr. B was subject to Sephadex LH-20 (60 g; methanol) to obtain Fr. B1 and Fr. B2. Fr. B1 was purified by reversed phase HPLC (Waters P150 instrument equipped with Phenomenex Kinetex PS C18 column, 5 µm, 20 × 150 mm) eluted with 25% acetonitrile at a flow rate of 15.0 mL/min to obtain **1** (*t~R~* = 5.1 min, 26.6 mg).

Fr. B2 was purified by reversed phase HPLC (Agilent 1260 instrument equipped with Phenomenex Kinetex PS C18 column, 3.5 µm, 10 × 150 mm) eluted with 35% acetonitrile at flow rate of 3.2 mL/min to obtain **2** (*t~R~* = 5.2 min, 2.3 mg).

3.5. Spectral Data of the Compounds {#sec3dot5-marinedrugs-18-00058}
-----------------------------------

**Shellmycin A** (**1**): yellow solid; \[α\]${}_{D}^{25}$ −261° (c 0.1, MeOH); UV (MeOH) λmax (log ε): 219 (2.78), 268 (4.36), 390 (1.83) nm; NMR data: [Table 1](#marinedrugs-18-00058-t001){ref-type="table"}; HR-MS *m*/*z* 469.1493, C~25~H~24~O~9~ (calcd for C~25~H~25~O~9~^+^, \[M + H\]^+^, 469.1493).

**Shellmycin B** (**2**): yellow oil; \[α\]${}_{D}^{25}$ −235° (c 0.1, MeOH); UV (MeOH) λmax (log ε): 218 (2.85), 267 (4.21), 385 (2.13) nm; NMR data: [Table 2](#marinedrugs-18-00058-t002){ref-type="table"}; HR-MS *m*/*z* 471.1648, C~25~H~26~O~9~ (calcd for C~25~H~27~O~9~^+^, \[M + H\]^+^, 471.1650).

**Shellmycin C** (**3**): yellow solid; \[α\]${}_{D}^{25}$ −98° (c 0.1, MeOH); UV (MeOH) λmax (log ε): 219 (2.35), 266 (4.20), 388 (1.68) nm; NMR data: [Table 3](#marinedrugs-18-00058-t003){ref-type="table"}; HR-MS *m*/*z* 469.1491 C~25~H~24~O~9~ (calcd for C~25~H~25~O~9~^+^, \[M + H\]^+^, 469.1493).

**Shellmycin D** (**4**): yellow solid; \[α\]${}_{D}^{25}$ −223° (c 0.1, MeOH); UV (MeOH λmax (log ε): 219 (2.36), 266 (4.16), 388 (1.83) nm; NMR data: [Table 4](#marinedrugs-18-00058-t004){ref-type="table"}; HR-MS *m*/*z* 469.1494, C~25~H~24~O~9~ (calcd for C~25~H~25~O~9~^+^, \[M + H\]^+^, 469.1493).

3.6. Computational Chemistry {#sec3dot6-marinedrugs-18-00058}
----------------------------

The systematically conformational searches were performed by the Pcmodel 10.0 software with a simulated annealing method and the MMFF94 force field. The conformers were further optimized by the B97-3C level while using Orca 4.2 software \[[@B32-marinedrugs-18-00058]\]. The 6-31G\*\* basis set is used by default. The theoretical calculations of the ECD data were conducted while using the TDDFT method at the CAM-B3LYP level in MeOH. The ECD spectra were simulated using the Multiwfn 3.6 \[[@B33-marinedrugs-18-00058]\] to get the Boltzmann-averaged ECD spectrum.

3.7. Cytotoxicity Assay {#sec3dot7-marinedrugs-18-00058}
-----------------------

The cytotoxicity of the compounds and positive control were evaluated against five tumorous human cell lines including non-small cell lung cancer (H1299, ATCC CRL-5803), malignant melanoma (A375, ATCC CRL-1619), hepatocellular carcinoma (HepG2, ATCC HB-8065), colorectal adenocarcinoma (HT29 ATCC HTB-38), and breast cancer (HCC1937, ATCC CRL-2336). Cancer cells were plated at a density of 1 × 10^4^ cells per well in 96-well plates and incubated at 37 °C, 5% CO~2~ for 24 h in DMEM-FBS medium. Cells were treated with different concentrations of shellmycins. The medium was removed, and 100 µL of resazurin-containing medium was added to each well after 24 h and 72 h. Cells were then incubated for 2 h, and fluorescence was measured (Cytation 3, BioTek) at excitation/emission wavelengths of 560/590 nm.

3.8. Antimicrobial Assay {#sec3dot8-marinedrugs-18-00058}
------------------------

*Candida albicans* ATCC 18804 used as indicator fungi, while *Staphylococcus aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212, *Bacillus subtilis* ATCC 6633, *Pseudomonas aeruginosa* ATCC 27853, and *Mycobacterium smegmatis* ATCC 700084 were used as indicator bacteria.

The MIC was determined by using a broth microdilution assay modified from the method. *Candida albicans* ATCC 18804 was grown in YPD broth and bacteria were grown overnight in LB broth and diluted to approximately 4 × 10^5^ CFU/mL then added 90 µL to the sterile 96-well polypropylene microtiter plates. Two-fold serial dilutions of compounds **1**--**4** in DMSO were added to the 96-well plates with concentrations ranging from 320 to 2.5 µg/mL. Plates were incubated at 37 °C overnight then read at 600 nm in a microplate reader.

4. Conclusions {#sec4-marinedrugs-18-00058}
==============

In conclusion, four novel tetrahydroanthra-γ-pyrone compounds named shellmycin A--D were isolated from the marine *Streptomyces* sp. shell-016. The structures of these four compounds were established by interpretation of 1D and 2D NMR, high-resolution ESI-MS data, and single crystal X-ray diffraction. An interesting fact was **3** and **4** are a pair of stereoisomers and their biological activity was significantly different. This study provides not only a valuable subject for future research on the structure--activity relationship and biosynthesis, but also an impetus for anti-cancer drug development.
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marinedrugs-18-00058-t001_Table 1

###### 

NMR spectroscopy data (MeOD-*d*~4~) for compound **1**.

  Pos.      δ~H~ (mult., *J* = Hz)        δc       ^1^H-^1^H COSY   HMBC
  --------- ----------------------------- -------- ---------------- ------------------------------
  2                                       174.9s                    
  3         6.73 (s)                      111.6d                    C-14, C-2, C-4, C-4a
  4                                       182.1s                    
  4a                                      120.6s                    
  5                                       138.0s                    
  6         7.47 (s)                      129.9d                    C-13, C-12a, C-7, C-4a, C-6a
  6a                                      142.6s                    
  7         7.43 (s)                      117.4d                    C-8, C-6, C-11a, C-6a, C-11
  7a                                      147.8s                    
  8         4.95 (dd, 7.5, 3.8)           69.0d    H-9              C-10, C-7, C-7a
  9         2.18, 2.37 (m)                32.7t    H-8, H-10        C-10, C-8, C-7a, C-11
  10        2.81, 3.00 (dq, 17.6, 4.6)    36.8t    H-9              C-9, C-8, C-11
  11                                      207.0s                    
  11a                                     113.3s                    
  12                                      165.8s                    
  12a                                     114.7s                    
  12b                                     159.1s                    
  13        4.16,4.26 (m)                 42.9t                     C-13-COOH, C-5, C-4a, C-6
  13-COOH                                 175.7s                    
  14                                      78.1s                     
  15        1.55 (s)                      24.0q                     C-3, C-2, C-16
  16        5.28 (d, 10.5)                71.5d    H-17             C-3, C-2, C-15
  17        5.73 (ddd, 11.7, 10.5, 1.5)   130.0d   H-16, H-18       C-19, C-16, C-14
  18        5.88 (dq, 11.7, 6.8)          130.1d   H-17, H-19       C-19, C-16
  19        1.92 (dd, 6.9, 1.8)           14.4q    H-18             C-17, C-16

marinedrugs-18-00058-t002_Table 2

###### 

NMR spectroscopy data (MeOD-*d*~4~) for compound **2**.

  Pos.      δ~H~ (mult., *J* = Hz)   δc       ^1^H-^1^H COSY   HMBC
  --------- ------------------------ -------- ---------------- ---------------------------
  2                                  174.9s                    
  3         6.72 (s)                 111.6d                    C-14, C-4a, C-2
  4                                  182.5s                    
  4a                                 121.1s                    
  5                                  138.4s                    
  6         7.59 (s)                 130.3d                    C-13, C-4a, C-7, C-12a
  6a                                 143.0s                    
  7         7.54 (s)                 117.7d                    C-8, C-11a, C-6, C-6a
  7a                                 148.3s                    
  8         5.00 (dd, 8.6, 3.9)      69.3d    H-9              
  9         2.21, 2.40 (m)           33.0t    H-8, H-10        
  10        2.87, 3.04 (m)           37.0t    H-9              
  11                                 207.3                     
  11a                                113.7s                    
  12                                 166.2s                    
  12a                                115.3s                    
  12b                                159.7s                    
  13        4.26-4.33 (m)            43.3t                     C-13-COOH, C-4a, C-6, C-5
  13-COOH                            176.2s                    
  14                                 78.5s                     
  15        1.65 (s)                 24.2q                     C-3, C-2, C-16
  16        4.19 (dd, 10.2, 1.8)     76.7d    H-17             
  17        1.58, 1.69 (m)           34.3t    H-16, H-18       
  18        1.47, 1.68 (m)           21.3t    H-17, H-19       
  19        1.02 (t, 6.9, 1.8)       15.1q    H-18             C-17, C-16, C-14

marinedrugs-18-00058-t003_Table 3

###### 

NMR spectroscopy data (MeOD-*d*~4~) for compound **3**.

  Pos.      δ~H~ (mult., *J* = Hz)   δc       ^1^H-^1^H COSY   HMBC
  --------- ------------------------ -------- ---------------- ---------------------------
  2                                  174.8s                    
  3         6.67 (s)                 109.8d                    C-14, C-4a, C-2
  4                                  182.6s                    
  4a                                 121.0s                    
  5                                  138.3s                    
  6         7.58 (s)                 130.4d                    C-13, C-4a, C-7, C-12a
  6a                                 143.0s                    
  7         7.54 (s)                 117.6d                    C-8, C-11a, C-6, C-6a
  7a                                 148.4s                    
  8         5.00 (dd, 8.7, 4.0)      69.4d    H-9              C-7, C-7a
  9         2.21, 2.40 (m)           33.1t    H-8, H-10        
  10        2.87, 3.04 (m)           37.1t    H-9              C-8, C-9
  11                                 207.2s                    
  11a                                113.8s                    
  12                                 166.2s                    
  12a                                115.1s                    
  12b                                159.7s                    
  13        4.28 (m)                 43.3t                     C-13-COOH, C-4a, C-6, C-5
  13-COOH                            176.1s                    
  14                                 74.8s                     
  15        1.82 (s)                 28.2q                     C-17, C-2, C-14
  16        6.25 (dd, 15.5, 1.3)     133.9d   H-17             C-14, C-18
  17        6.05 (dd, 15.5, 5.8)     136.3d   H-16, H-18       C-14, C-18
  18        4.32 (m)                 69.5d    H-17, H-19       C-16
  19        1.26 (t, 6.9, 1.8)       24.4q    H-18             C-17, C-18
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###### 

NMR spectroscopy data (MeOD-*d*~4~) for compound **4**.

  Pos.      δ~H~ (mult., *J* = Hz)   δc       ^1^H-^1^H COSY   HMBC
  --------- ------------------------ -------- ---------------- ---------------------------
  2                                  174.9s                    
  3         6.67 (s)                 109.8d                    C-14, C-4a, C-2
  4                                  182.6s                    
  4a                                 121.0s                    
  5                                  138.3s                    
  6         7.57 (s)                 130.4d                    C-13, C-4a, C-7, C-12a
  6a                                 143.0s                    
  7         7.53 (s)                 117.6d                    C-8, C-11a, C-6, C-6a
  7a                                 148.4s                    
  8         5.00 (dd, 8.7, 4.0)      69.4d    H-9              C-7, C-7a
  9         2.21, 2.40 (m)           33.1t    H-8, H-10        
  10        2.87, 3.04 (m)           37.1t    H-9              C-8, C-9
  11                                 207.2s                    
  11a                                113.8s                    
  12                                 166.2s                    
  12a                                115.1s                    
  12b                                159.6s                    
  13        4.24-4.31 (m)            43.3t                     C-13-COOH, C-4a, C-6, C-5
  13-COOH                            176.1s                    
  14                                 74.9s                     
  15        1.82 (s)                 28.3q                     C-17, C-2, C-14
  16        6.26 (d, 15.5)           133.8d   H-17             C-14, C-18
  17        6.05 (dd, 15.5, 5.6)     136.2d   H-16, H-18       C-14, C-18
  18        4.33 (m)                 69.4d    H-17, H-19       C-16
  19        1.25 (t, 6.9, 1.8)       24.4q    H-18             C-17, C-18

marinedrugs-18-00058-t005_Table 5

###### 

Anti-microbial activity (MIC µg/mL) of compounds **1**--**4**.

  Pathogen Strains                        MIC (µg/mL)                   
  --------------------------------------- ------------- ------- ------- -------
  *Candida albicans* ATCC 18804           \>100         \>100   \>100   \>100
  *Staphylococcus aureus* ATCC 25923      3             21      46      16
  *Enterococcus faecalis* ATCC 29212      6             13      36      21
  *Bacillus subtilis* ATCC 6633           11            26      32      21
  *Pseudomonas aeruginosa* ATCC 27853     \>100         \>100   \>100   \>100
  *Mycobacterium smegmatis* ATCC 700084   \>100         \>100   \>100   \>100
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###### 

Inhibitory concentration (IC~50~, µM) of compounds **1**--**4** against various tumor cell lines (cis-platinum as positive control).

  Compound         IC~50~ (µM)                                                           
  ---------------- ------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  **1**            5.22          0.69   8.63   1.32   4.22   0.89   4.69   0.85   9.68   2.62
  **2**            7.18          0.95   10.3   2.62   5.67   1.35   6.12   1.12   11.6   3.11
  **3**            40.3          11.3   \>50   26.3   11.3   5.03   13.0   4.33   \>50   12.6
  **4**            6.04          0.78   10.1   2.15   5.16   1.11   5.37   1.02   10.3   2.89
  *cis*-platinum   23.1          9.32   21.2   7.3    \>50   18.9   \>50   \>50   \>50   \>50
